AstraZeneca will fund 55 more PhD’s at the University of Cambridge, the University has announced. 

The Cambridge based pharmaceutical company, responsible for developing one of the world's first Covid-19 vaccines, has funded more than 100 PhD students at the University over the last 20 years.

Kathryn Chapman, the University’s point of contact with AstraZeneca said: “Cambridge University and AstraZeneca see the future of medicine happening at the intersection of different disciplines, where biological understanding of disease processes and the chemistry of how drugs work, meets engineering and artificial intelligence.”

Professor Andy Neely, pro-vice-chancellor for enterprise, added: “Training the next generation of brilliant scientists who are able to collaborate with colleagues in different disciplines and with industry partners will be critical to getting new treatments to patients.”

Each student will have both an academic and industry supervisor and gain access to AstraZeneca’s new Discovery Centre, home to more than 2,200 scientists on Cambridge biomedical campus.